Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Neoplasms 32Colorectal Neoplasms 32Neoplasm Metastasis 31Breast Neoplasms 30Prostatic Neoplasms 29Pancreatic Neoplasms 25Ovarian Neoplasms 24Multiple Myeloma 23Recurrence 22Melanoma 22Squamous Cell Carcinoma of Head and Neck 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Non-Hodgkin 17Endometrial Neoplasms 17Triple Negative Breast Neoplasms 16Lung Neoplasms 15Leukemia, Myeloid, Acute 15Glioblastoma 15Stomach Neoplasms 14Lymphoma, Large B-Cell, Diffuse 14Burkitt Lymphoma 14Advanced Solid Tumor 13Small Cell Lung Carcinoma 12Colonic Neoplasms 12Carcinoma, Renal Cell 12Lymphoma, Follicular 11Lymphoma 11Advanced Solid Tumors 11Glioma 10

Interventions

olaparib 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoid Tumor × 30 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡